Identity, mechanisms and early life impacts of transporter interfering compounds

转运蛋白干扰化合物的特性、机制和早期生命影响

基本信息

  • 批准号:
    10179393
  • 负责人:
  • 金额:
    $ 55.86万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-06-01 至 2023-05-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY Prenatal exposures to environmental chemicals have been shown to cause adverse later life health effects, often involving disorders of reproductive dysfunction. The overall goal of this research is to understand the mechanisms governing accumulation of environmental chemicals in the embryo, so that we can predict and mitigate the negative effects of these exposures. In this proposal, we address two key questions with regard to xenobiotic accumulation in the embryo, with a specific focus on the role of xenobiotic transporters during primordial germ cell (PGC) formation. First, we ask how the program of development leads to changes in xenobiotic transporter expression, and thus generates windows of susceptibility or resistance to xenobiotic accumulation. Second, we ask how real-world chemical mixtures, containing both substrates and inhibitors of transporters, impact the efficacy of this conserved, protective system. Aim 1 uses a powerful in vitro molecular evolution technology to rapidly evolve, validate, and use antibody-like binders called nanobodies to characterize xenobiotic transporter proteins in human PGC-like cells (PGLCs) and in model organism embryos (sea urchin and zebrafish). Aim 2 applies biochemical and cellular approaches to determine relevant environmental ligands of human and model system xenobiotic transporters, and takes advantage of a powerful molecular structure determination pipeline to dissect the molecular mechanisms of these interactions. Aim 3 uses models and molecular targets from Aims 1 and 2 to test the hypothesis that PGCs are vulnerable to the interfering effects of environmental chemicals on the transporter defense system, and that disruption of this system leads to decreased reproductive fitness after xenobiotic challenge. This results will provide new insights into how environmental and developmental factors act in combination to govern the susceptibility of the nascent embryonic germ line to teratogens.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

GEOFFREY A CHANG其他文献

GEOFFREY A CHANG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('GEOFFREY A CHANG', 18)}}的其他基金

Biosynthesis of marine terpenoid natural products
海洋萜类天然产物的生物合成
  • 批准号:
    10737210
  • 财政年份:
    2023
  • 资助金额:
    $ 55.86万
  • 项目类别:
Synthetically-evolved and engineered Nanobodies selective for Cb isoforms of PKA
对 PKA Cb 亚型具有选择性的合成进化和工程纳米抗体
  • 批准号:
    10525796
  • 财政年份:
    2022
  • 资助金额:
    $ 55.86万
  • 项目类别:
Nanobody inhibitors of proton-sensing G protein-coupled receptors
质子感应 G 蛋白偶联受体的纳米抗体抑制剂
  • 批准号:
    10216432
  • 财政年份:
    2021
  • 资助金额:
    $ 55.86万
  • 项目类别:
TDP-43 acetylation, phase separation, aggregation, and clearance by antibody-mediated degradation
TDP-43 乙酰化、相分离、聚集和抗体介导的降解清除
  • 批准号:
    10380036
  • 财政年份:
    2021
  • 资助金额:
    $ 55.86万
  • 项目类别:
TDP-43 acetylation, phase separation, aggregation, and clearance by antibody-mediated degradation
TDP-43 乙酰化、相分离、聚集和抗体介导的降解清除
  • 批准号:
    10184466
  • 财政年份:
    2021
  • 资助金额:
    $ 55.86万
  • 项目类别:
Development of low-cost, field-ready nanobodies against snake venom
开发低成本、可现场使用的抗蛇毒纳米抗体
  • 批准号:
    10255596
  • 财政年份:
    2021
  • 资助金额:
    $ 55.86万
  • 项目类别:
TDP-43 acetylation, phase separation, aggregation, and clearance by antibody-mediated degradation
TDP-43 乙酰化、相分离、聚集和抗体介导的降解清除
  • 批准号:
    10594973
  • 财政年份:
    2021
  • 资助金额:
    $ 55.86万
  • 项目类别:
Down syndrome, early cataracts, eye diseases, and beta-amyloid conformers
唐氏综合症、早期白内障、眼部疾病和 β-淀粉样蛋白构象异构体
  • 批准号:
    9893680
  • 财政年份:
    2019
  • 资助金额:
    $ 55.86万
  • 项目类别:
Down syndrome, early cataracts, eye diseases, and beta-amyloid conformers
唐氏综合症、早期白内障、眼部疾病和 β-淀粉样蛋白构象异构体
  • 批准号:
    10018872
  • 财政年份:
    2019
  • 资助金额:
    $ 55.86万
  • 项目类别:
Identity, mechanisms and early life impacts of transporter interfering compounds
转运蛋白干扰化合物的特性、机制和早期生命影响
  • 批准号:
    10424481
  • 财政年份:
    2018
  • 资助金额:
    $ 55.86万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了